Eventide Asset Management MAZE Position
Active5-Fund ConvergenceEventide Asset Management initiated a new position in Maze Therapeutics, Inc. (MAZE) in Q4 2025, holding $13.4M worth of shares across 324,041 shares.
MAZE is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for MZE829 in 167 days (Sep 30, 2026), making the timing of Eventide's position particularly relevant.
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Full company profile →Short Interest
8.7%
7.6 days to cover
Frequently Asked Questions
Does Eventide Asset Management own MAZE?
Yes. As of Q4 2025, Eventide Asset Management holds 324,041 shares of Maze Therapeutics, Inc. (MAZE) valued at $13.4M. This data comes from their SEC 13F filing.
How many hedge funds own MAZE?
5 specialist biotech hedge funds currently hold MAZE, including Deep Track Capital, Casdin Capital, Foresite Capital and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy MAZE?
Eventide Asset Management's position in MAZE was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's MAZE position increasing or decreasing?
Eventide Asset Management initiated a new position in MAZE in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MAZECompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →